274 results about "Tumor antigen" patented technology

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

A method for treating tumors using a combination of an oncolytic virus vaccine and immune cells. The method specifically includes the following step: treating the tumors by using a combination of the immune cells and the oncolytic virus vaccine; the oncolytic virus vaccine includes a recombinant oncolytic virus expressing a tumor antigen and is used for targeting the tumor cells; the immune cells express a chimeric antigen receptor paired with the tumor antigen, and are used for killing or destroying the tumor cells targeted; the recombinant oncolytic virus includes an M protein, G protein, N protein, P protein and L protein subjected to site-directed mutagenesis. The tumor antigen expressed by the oncolytic virus vaccine can guide the immune cells to reach the target tumor tissue center, achieving a curative effect where 1+1 is greater than 2, with a tumor cell killing rate being up to 100% at most.

Provided herein are tumor-antigen VGLL1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL1 are also provided.

Provided are the construction, preparation and use of a functionally enhanced universal CAR-DNT cell. Specifically, provided is a chimeric antigen receptor construct. A CAR function-enhancing element and IL-10 are sequentially fused to the C-terminus of a tumor antigen-targeting CAR via a self-cleaving peptide, and the CAR construct is introduced into a DNT cell, thereby obtaining a functionally enhanced universal CAR-DNT cell, namely, an IL10-CD19-CAR-mbIL15-DNT cell. The cell specifically targets CD19, and has a stronger and more sustained cell killing activity and better safety, thus providing a new therapy for CD19-mediated diseases.

The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of. (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.

The application belongs to the technical field of biological nanomaterials, and particularly relates to an immune activation nanosheet as well as a preparation method and application thereof. The immune activation nanosheet comprises a two-dimensional montmorillonite nanosheet with a sheet layer structure, and manganese ions and tumor antigens loaded in the interlayer of the two-dimensional montmorillonite nanosheet. The mass ratio of the manganese ions to the montmorillonite is 1:5-1:20, and the mass ratio of the tumor antigens to the montmorillonite is 1:1-1:10. The immune activation nanosheet has the characteristics of good oral stability, high mucosal targeting, strong immune efficacy, etc. The stability of the immune activation nanosheet in the gastrointestinal tract is good, the immune activation nanosheet can be effectively enriched in the small intestine, a vaccine inoculation pool is formed, the intestinal immune tolerance can be overcome, the immune effect is enhanced, and the immune activation nanosheet has a clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

The present invention addresses the problem of providing a novel treatment method for T-cell tumors that can induce cell damage in tumor cells and can be used in the treatment of a T-cell tumor of a subject with T-cell dysfunction. The present invention provides a therapeutic agent for a T-cell tumor of a subject with T-cell dysfunction, said therapeutic agent comprising a bispecific antigen-binding molecule, wherein the bispecific antigen-binding molecule includes (1) at least one section that specifically binds to a target tumor antigen expressed in T-cell tumor cells, and (2) at least one section that specifically binds to an antigen which is a normal T-cell-side target antigen and has a subtype, provided that the target tumor antigen expressed in T-cell tumor cells is not present in normal T-cells, or if present, the normal T-cells are substantially not activated when the bispecific antigen-binding molecule binds to the antigen that is present in the normal T-cells and is the same as the target tumor antigen, and a sufficient ratio of the subtype of the normal T-cell-side target antigen is present such that the normal T-cells are activated by the bispecific antigen-binding molecule binding to the normal T-cell-side target antigen and a sufficient number of activated T-cells for treatment of the T-cell tumor are provided.

A polynucleotide and a composition thereof, the composition comprising a nucleic acid that encodes a human IL13Rα2 polypeptide, a nucleic acid that encodes an immunoglobulin Fc segment, and at least one nucleic acid that encodes other tumor antigens. The composition can induce immune responses against IL13Rα2 and other tumor antigens, and is thus used for preventing / treating tumors.

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APCs.

A combination of an immune cell that expresses a receptor that recognizes a tumor antigen and a benzamide-based HDAC inhibitor. The invention further discloses a kit containing the immune cells and the benzamide HDAC inhibitor and a method for combined treatment of diseases such as cancer.

The invention discloses application of a nerve injury induction protein 1 in preparation of a gastric cancer diagnosis and treatment product. The invention finds that the overexpression of NINJ1 not only can enhance the sensitivity of gastric cancer cells to ferroptosis by down-regulating the expression of aldehyde ketoreductase AKR1C1 / 2 / 3, but also can up-regulate the expression of MHC-I molecules on the surfaces of tumor cells, promote the presentation of tumor antigens and increase the infiltration of CD8 + T cells, so that the dual anti-tumor function is exerted; therefore, NINJ1 overexpression and an immune checkpoint inhibitor (such as a PD-L1 antibody) or a ferroptosis inducer are combined for use, so that the immunotherapy effect can be synergistically improved. The invention provides a brand new targeting strategy for overcoming the immune drug resistance of gastric cancer and improving the treatment effect, and has important clinical transformation value.

The present application relates to the technical field of polymer chemistry, and particularly relates to a responsive dendritic polyamino acid modified polyurethane and a preparation method and application thereof.The responsive dendritic polyamino acid modified polyurethane has a structure shown in formula I.The responsive dendritic polyamino acid modified polyurethane provided by the present application can specifically expose positive dendritic polylysine in the unique acidic environment of tumor tissue, trigger immunogenic death of tumor cells, release tumor antigens, and comprehensively activate an anti-tumor immune response.Meanwhile, the positive dendritic polylysine causes an increase in reactive oxygen species (ROS) of tumor cells, oxidizes a diselenium bond in the polyurethane into selenic acid, reduces the expression of immune checkpoints of tumor cells, reverses the immunosuppressive microenvironment of tumor tissue, realizes synergistic treatment of immune activation and reversal of the tumor immunosuppressive microenvironment, and realizes a better tumor immunotherapy effect.

The present invention relates to a bispecific anti-tumor antigen / anti-HSG antibody having screened light and heavy chain variable domains, which is capable of improving the pre-targeting of tumors for the specific delivery of therapeutic or diagnostic agents. The antibodies have a significant affinity for tumor antigens and stay at desired sites for a sufficient time. Antibodies that do not bind to the antigen can be rapidly cleared from the body, minimizing exposure of normal tissue. A humanized anti-HSG antibody is bound to each of a group containing histamine-succinyl-glycine (HSG) and a tumor antigen with high affinity. The bispecific antibodies can be further Fc silenced, resulting in additional properties, such as reduced binding to Fc [gamma] R and FcRn, thereby modulating effector function and regulating half-life. These antibodies are useful in the diagnosis and treatment of subjects suffering from malignancies.

This invention discloses a universal detection method for tumor antigen-specific thymus-dependent lymphocytes in a broad population of East Asia, applicable to lung cancer and gastrointestinal cancers. The broad-spectrum T-cell epitope peptide library used in this detection method contains specific antigen T-cell epitope peptides presented by 13 HLA-A molecules, 15 HLA-B molecules, and 14 HLA-C molecules with an allele frequency greater than 1% in the East Asian population. The total gene frequencies of these dominant HLA-A, B, and C molecules account for approximately 95%, 71%, and 93% of the Chinese population, respectively, and are similar in total gene frequencies in Northeast and Southeast Asian populations. Therefore, this detection method is applicable to the vast majority of individuals in this region, providing a universal method for evaluating specific tumor antigen-specific T-cell immune function in patients with lung cancer or gastrointestinal tumors.

Methods are disclosed for the treatment of cancer in a subject, wherein the subject is, or is predicted to be, resistant to immune checkpoint inhibitor (ICI) cancer treatment. A polyspecific binding molecule that binds to CD16A on innate immune cells and a tumor antigen, such as EGFR or FOLR1, on tumor cells, is administered to the resistant subject. The polyspecific binding molecule can sensitize the tumor towards treatment with an ICI, such as a PD-L1 or PD-1 inhibitor.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

A patient screening method for oncolytic virus therapy, comprising: detecting HLA typing of a patient; and further comprising detecting a tumor antigen expressed by a tumor cell, and / or detecting whether the patient expresses a protein in an antigen presentation pathway.

To provide systems and methods for histotripsy and immune therapies.SOLUTION: In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of tumor immunity, and particularly relates to a tumor antigen and chemotactic factor co-coding system and application thereof. The invention provides a tumor antigen and chemotactic factor co-coding system. The tumor antigen and chemotactic factor co-coding system comprises a nucleotide sequence for coding a tumor antigen and a nucleotide sequence for coding a chemotactic factor. The tumor antigen and chemotactic factor co-coding system can flexibly replace an antigen sequence and chemotactic factor combination, is adaptive to different tumor types and various immunotherapy requirements, can be expanded to various solid tumor treatment scenes through a customized antigen-chemotactic factor combination in the future, and has a wide application prospect. The broad-spectrum application in tumor treatment means including tumor neoantigen vaccines, adoptive cell therapy and the like is realized.

The invention relates to a polynucleotide and a composition thereof. The polynucleotide comprises a nucleic acid for coding a human IL13R alpha2 polypeptide, a nucleic acid for coding an Fc segment of immunoglobulin and at least one nucleic acid for coding other tumor antigens, the composition is capable of eliciting an immune response against IL13R [alpha] 2 and other tumor antigens for use in the prevention / treatment of tumors.

Compositions and methods of glycosylated virus-like particles (VLPs) displaying user-defined antigens and optionally encapsidating TLR ligands for targeting dendritic cell lectins have been developed. The VLPs employ ligands for a DC lectin e.g., DC-SIGN to activate dendritic cells (DC) and drive proliferation of antigen-specific CD8 and CD4-T cells specific for a user-defined antigen, such as a tumor antigens. In some forms, the compositions include aryl-mannose ligands to effectively generate DC-mediated TH-1 T cell responses to the user-defined antigen.

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a targeting bioactive agent (TBA); a payload bioactive agent (PBA) covalently linked to the targeting bioactive agent (TBA) directly or indirectly; and, optionally, a polymer forming nanoaggregates. The pharmaceutical composition can comprise Ag+ tumor cytotoxicity to tumor cells having a tumor antigen (Ag+ tumor cells) and Ag− tumor cytotoxicity to tumor cells free from a tumor antigen (Ag− tumor cells). The pharmaceutical composition can be an antibody-drug conjugate (ADC) for treating cancers having tumor antigen positive (Ag+) tumor cells, tumor antigen negative (Ag−) tumor cells, or heterogenous cancers having both tumor antigen positive (Ag+) tumor cells and tumor antigen negative (Ag−) tumor cells.

The invention is directed to methods for determining antigen-specific T cells generally and to T cell receptors which bind an epitope of the Wilms' tumor antigen-1 (WT1) protein specifically. The disclosure also provides polynucleotides encoding the TCRs, engineered cells exogenously expressing the TCRs, and methods of making and using the TCRs and / or cells expressing the TCRs.